Pfizer's mRNA Influenza Vaccine Fails in Clinical Trial Among Seniors, FDA Commissioner Says

Pfizer's experimental mRNA influenza vaccine failed to provide protection for seniors, according to FDA Commissioner Dr. Marty Makary. The vaccine performed better in a trial among healthy people aged 18-64, but among seniors, 0.5% suffered influenza-like illness and had laboratory-confirmed influenza cases. Many more seniors reported adverse reactions compared to recipients of an existing vaccine. Makary suggested the vaccine won't receive approval without new data proving its effectiveness.